Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
06:10pm, Monday, 05'th Aug 2024
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
04:01pm, Monday, 05'th Aug 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter.
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
11:11am, Monday, 15'th Jul 2024
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 29'th May 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
07:00am, Tuesday, 07'th May 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript
08:34pm, Monday, 06'th May 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Of
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Monday, 06'th May 2024
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:10am, Tuesday, 30'th Apr 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
07:00am, Tuesday, 30'th Apr 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indication
Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
07:00am, Wednesday, 17'th Apr 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunol
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
07:00am, Wednesday, 06'th Mar 2024
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immuno
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
10:04pm, Wednesday, 07'th Feb 2024
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 07'th Feb 2024
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.
